Review Article

Results of redo pulmonary metastasectomy

Vincenzo Ambrogi¹, Alessandro Tamburrini², Riccardo Tajé³

¹Thoracic Surgery Unit, Tor Vergata University Polyclinic, Rome, Italy; ²Thoracic Surgery Unit, Southampton University Hospital, Southampton, UK; ³Tor Vergata University School of Medicine, Rome, Italy

Contributions: (I) Conception and design: V Ambrogi, R Tajé; (II) Administrative support: V Ambrogi; (III) Provision of study materials or patients: R Tajé; (IV) Collection and assembly of data: V Ambrogi, R Tajé; (V) Data analysis and interpretation: V Ambrogi, R Tajé; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Vincenzo Ambrogi. UOC di Chirurgia Toracica, Policlinico Università di Roma Tor Vergata, Viale Oxford 81, 00133 Rome. Italy. Email: ambrogi@med.uniroma2.it.

Abstract: Repeat surgical resection (redo) for pulmonary metastases is a questionable, albeit intriguing topic. We performed an extensive review of the literature, to specifically analyze results of redo pulmonary metastasectomies. We reviewed a total of 3,523 papers. Among these, 2,019 were excluded for redundancy and 1,105 because they were not completely retrievable. Out of 399 eligible papers, 183 had missing information or missing abstract, while 96 lacked data on survival. A total of 120 papers dated from 1991 onwards were finally included. Data regarding mortality, major morbidity, prognostic factors and long-term survivals of the first redo pulmonary metastasectomies were retrieved and analyzed. Homogeneity of data was affected by the lack of guidelines for redo pulmonary metastasectomy and the risks of bias when comparing different studies has to be considered. According to the histology sub-types, redo metastasectomies papers were grouped as: colorectal (n=42), sarcomas (n=36), others (n=20) and all histologies (n=22); the total number of patients was 3,015. Data about chemotherapy were reported in half of the papers, whereas targeted or immunotherapy in 9. None of these associated therapies, except chemotherapy in two records, did significantly modify outcomes. Disease-free interval before the redo procedure was the prevailing prognostic factor and nearly all papers showed a significant correlation between patients’ comorbidities and prognosis. No perioperative mortality was reported, while perioperative major morbidity was overall quite low. Where available, overall survival after the first redo metastasectomy ranged from 10 to 72 months, with a 5-years survival of approximately 50%. The site of first recurrence after the redo procedure was mainly lung. Despite the data retrievable from literature are heterogeneous and confounding, we can state that redo lung metastasectomy is worthwhile when the lesions are resectable and the perioperative risk is low. At present, there are no “non-surgical” therapeutic options to replace redo pulmonary metastasectomies.

Keywords: Pulmonary metastasectomy; redo metastasectomy; target therapy; immune therapy

doi: 10.21037/jtd-19-4064
View this article at: http://dx.doi.org/10.21037/jtd-19-4064

Introduction

Within the routine practice of a general thoracic surgeon, it is not uncommon to encounter cases of pulmonary metastases. Their incidence is indeed quite high, ranging from 20% to 45% in patients who died from extrathoracic malignancies (1,2). After initial anecdotal attempts, the first case of long-term survival following resection of pulmonary metastasis from a renal adenocarcinoma was reported by Barney and Churchill in 1939 (3). The first feasibility study of pulmonary resection for metastases was undertaken 25 years later by Thomford et al. (4). Since then, numerous papers about lung metastasectomy have been published, displaying encouraging results but low level of evidence (5). In this regard, the actual goal of this procedure is somehow debatable (6), and the only randomized controlled trial is
still running (7). A task force aiming to clarify the value of pulmonary metastasectomy was established by The Society of Thoracic Surgeons (8), but the statement determined by this consensus of experts cannot be presented as guideline, due to weakness in level of evidence (9).

Furthermore, if lack of evidence appears to be a prominent problem in metastasectomy, redo metastasectomy is a true no man’s land.

In this respect, only few studies are specifically focused on repeat lung resections for metastases, thus results and effectiveness of redo metastasectomy effectively derive from a relatively limited number of patients within larger studies addressing the first pulmonary metastasectomy. Nonetheless, redo pulmonary resection is actually frequently performed. Data from a large review of 18 studies reporting on pulmonary metastasectomy for sarcoma in a total of 1,357 cases showed that 43% (n=580) of the patients underwent redo pulmonary metastasectomy (10). The principal investigator of this review (VA) has over 25 years of experience in redo pulmonary metastasectomy and in 2015 he reported on 113 patients who had undergone at least one redo pulmonary metastasectomy, 54 of them had had two, 31 three, 8 four and 3 up to five repeated operations (11), respectively.

In this current review we summarized most of the studies on redo pulmonary metastasectomy-for different types of malignancies. We also investigated the possible role of molecular subtypes of cancers and we analyzed the results of surgery in association with chemotherapy, immunotherapy or targeted therapy. Hence, we examined the surgical approach to frail patients, who represent a substantial percentage of patients undergoing repeat metastasectomy. Eventually, we analyzed the long-term survival results and tried to outline the current evidences for redo metastasectomy.

Redo pulmonary metastasectomy in specific settings

A total of 120 studies were included for the final evaluation, and the entire sample size consisted of 3,015 patients. We analyzed these amounts of studies into different sections: colorectal, sarcomatous, other and not focused on a specific histotype. Some of the publications dealing with metastases from colorectal cancer are mostly focused on colon cancer (12-24), others mostly on rectal cancer (25-38) and in the remaining the primary lesion location was unknown (28,33,39-53). Publications focused on sarcomatous metastases gather studies mostly emphasizing hard tissue sarcomas (54-68), others mostly soft tissue sarcomas (69-76) and the residual mostly other sarcomas (77-89). The remaining studies mentioned lung metastases from primary tumors other than colorectal cancers and sarcomas (90-109) or did not focus on a specific histotype (40,110-130). The process of selecting the studies is shown in the PRISMA flow chart (Figure 1). In 79 papers, male was the prevalent gender of patients. Mean age at the time of the first redo metastasectomy was 55.4±12.1 years and mean follow-up time was 42.2±22.7 months. According to the available data, the mean disease-free interval before the first redo operation was 8.4±6.5 months. In all studies that mentioned it, there was no postoperative mortality. The data about major peri-operative morbidity of the redo procedure was often missing but, when reported, it was negligible in most of studies. Only in one case (19), peri-operative morbidity was two-fold greater than at the time of the first pulmonary metastasectomy.

Some of the papers focused on a specific histological type of cancers while others featured mixed histologies grouped together. For the purposes of this review, we preferred to present the data dividing the studies in groups according to the histology types. The groups we established were the following: colorectal carcinomas (n=42), sarcomas (n=36), other cancers (n=20), all histologies together (n=22). Total number of patients for each subgroup involved in the records are summarized in Table 1. The studies collected in our review cover a time span of nearly 30 years (Figure 2) and come from different research groups spread all over the world (Figure 3).

Reports focused on colorectal cancer

Pulmonary metastases from colorectal cancer represent the most common instance in which redo metastasectomy is performed, and this is valid also for our review. It has also been recently documented that their percentage has constantly increased from less than 15% in the 1960's to well over 20% in the 2000s (131). In this review, redo pulmonary metastasectomy in patients with primary colorectal cancer was performed in 42 out of the 120 selected studies. The majority of records reported a higher frequency of diagnosis for males under the age of 65. When reported, there was no difference in regard to the location of the primary tumor in the colon (most frequent in 13 studies) or in the rectum (more frequent in 14 studies). Repeat lung resections were more likely to
be performed in patients with colorectal cancer at advanced stages (III or IV TNM stage and Duke C or D), as stated in all papers (n=20) where this data was available.

Only 11 records reported on the preferred surgical approach, which was videothoracoscopic surgery (VATS) in 5 studies and thoracotomy in 6. Subanatomic lung resections were more often performed in 14 studies and anatomical resections in 4, with the other 14 publications not mentioning the extent of resection.

There was no postoperative deaths after the first redo metastasectomy in all records, while major morbidity was hardly mentioned. Only one study reported major

Figure 1 PRISMA algorithm for record inclusion.

Table 1 Number of records and subjects at the different redo included in the review

<table>
<thead>
<tr>
<th>Primitive tumor</th>
<th>Records (n)</th>
<th>First Redo (n)</th>
<th>Second (n)</th>
<th>Third (n)</th>
<th>Fourth (n)</th>
<th>Fifth (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal</td>
<td>42</td>
<td>866</td>
<td>52</td>
<td>2</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>Sarcoma</td>
<td>36</td>
<td>601</td>
<td>45</td>
<td>4</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>Other</td>
<td>20</td>
<td>127</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>All histotypes</td>
<td>22</td>
<td>1,421</td>
<td>288</td>
<td>110</td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>120</td>
<td>3,015*</td>
<td>386</td>
<td>115</td>
<td>13</td>
<td>1</td>
</tr>
</tbody>
</table>

*Repetitions cannot be excluded.
complications after 21 redo procedures including atrial fibrillation (n=3), prolonged air leak (n=2), bleeding requiring transfusions (n=1) and bleeding requiring re-operation (n=1) (19).

In the setting of redo metastasectomies, it is not easy to distinguish between neoadjuvant and adjuvant treatments. Chemotherapy given at some stage was mentioned in 23 publications. Among them, neoadjuvant chemotherapy was reported in 6 records and adjuvant chemotherapy in 16.

In 4 studies, both neoadjuvant and adjuvant chemotherapy were administered. Only 6 papers stated which drugs and protocols were used, and among them targeted therapy was utilized in 4 (22,30,44,51). When statistical analysis was performed (2 reports), biological chemotherapy regimens did not result to be independent statistically significant prognostic indicators of overall survival (22,51). In Figure 4, we summarize the prognostic factors influencing overall survival at multivariate analysis.
Reports focused on sarcoma

Redo metastasectomy in patients with sarcoma was documented in 36 out of the 120 records. Of these records, 15 were focused mostly on hard tissue sarcomas (54-68), 8 were focused mostly on soft tissue sarcomas (69-76) and 13 mostly on other sarcomas (77-89). Prevalence of males was exhibited in 20 of the studies. Because of the nature of the disease, the population of patients treated with redo metastasectomy for sarcomas displayed a significant younger age compared to other histotypes. In 5 papers, patients’ population consisted mostly of children, with a median age of 18 years-old, whereas in another 29 the population featured young adults aged between 18 and 65.

The surgical approach of choice for the first redo pulmonary metastasectomy was thoracotomy in 12 records, and subanatomic lung resections were preponderant in 19 studies. Also in redo metastasectomy for sarcomas, no post-operative mortality was observed and data about post-operative morbidity were scant. Two studies clearly stated that the redo procedure did not imply an increased morbidity (78,79).

Administration of chemotherapy was reported in 14 papers. In 3 of them (56,79,82), neoadjuvant treatment was accomplished, while in the other 11 adjuvant treatment after the first metastasectomy was chosen (56,57,59,66,71,73,79,81,82,84,88). The protocols utilized were stated in 7 publications (56-60,79,84), none of them had targeted therapy nor immunotherapy among the chemotherapeutic agents. The prognostic factors at multivariate analysis influencing overall survival are shown in Figure 5.

Reports focused on tumors other than colorectal and sarcoma

Twenty papers in total dealt with lung metastases from primary tumors other than colorectal cancers and sarcomas (90-109). In view of the small number of studies for each different primary, we deemed more appropriate to present them comprehensively as an “other tumors” group. Out of an overall population of 1,046 patients undergoing lung metastasectomies, 186 patients underwent at least one redo metastasectomy, 13 a second redo and one patient a third redo. Male was again the predominant gender, as displayed by 13 studies. Median age was between 18 and 65 in 2 publications, while only in 2 it was over 65.

Surgical approach (VATS or thoracotomy) was rarely mentioned, while in 13 records it was reported that the performed resections were mostly subanatomic (90,91,93-97,100,102,104-106,109). The use of chemotherapy was generically reported in 13 records, but neoadjuvant treatment was clearly mentioned in 3 studies (93,95,107) and adjuvant therapy in 6 (91,93,95,96,98,108), respectively.
Among the 120 papers reviewed, 22 of them did not focus on a specific histotype, but rather dealt with various types of primary cancers (40,110-130). These records incorporate a total of 6,072 patients, 1,332 of them underwent at least one redo, 318 underwent two, 114 underwent three, 22 underwent four and 3 underwent five redo metastasectomies, respectively.

In 20 records male was the prevalent gender among operated patients were prevalent. The median age was <18 years old in 4 records, between 18 and 65 in 16 and above >65 in one, as a single study did not report it. Interestingly, in the majority of papers, thoracotomy was the most used surgical approach for redo metastasectomies, and subanatomic resection was the preferred procedure.
Data about postoperative mortality are generally missing but, whenever available, they report no mortality. According to 12 studies, chemotherapy after diagnosis of the primary tumor was utilized at some stage, as neoadjuvant treatment before the redo metastasectomy in 4 papers and as adjuvant therapy following redo resection in 5 (40,111,126,127,130). The prognostic indicators of overall survival at multivariate analysis for this group are summarized in Figure 6.

**Redo metastasectomy associated with non-surgical therapies**

Overall, data about chemotherapy were available in half of the records, although only 26 of them reported the drugs or protocols used. These data are challenging to interpret, as it is not always clear whether the treatments administered are adjuvant or neoadjuvant. In 10 studies, chemotherapy was a predictor of longer overall survival at univariate analysis, and in 2 of them chemotherapy proved to be an independent predictor also at multivariate analysis (50,56). Nevertheless, we also found that chemotherapy was a negative prognostic factor in 2 papers reporting metastasectomies for sarcoma (74,89), probably due to the more aggressive nature of the cancers.

Targeted therapy or immunotherapy were used as single-therapy or in combination with traditional cytotoxic drugs in 9 studies (22,30,44,51,91,102,104,109,129), 4 of which focused on colorectal cancers (22,30,44,51). A statistically significant improved overall survival in patients undergoing redo metastasectomy for colorectal cancer who had adjuvant biological therapy was found in only one case (51). In another study instead (22), the use of adjuvant cytotoxic + targeted therapy did not affect disease recurrence after the first pulmonary metastasectomy, whereas the distribution of the metastases (unilateral vs. bilateral) and the stage of the primary cancer were statistically significant factors. In the other studies focused on different primary tumors, the use of targeted or immunotherapy, either within adjuvant or neoadjuvant setting, proved to be a significant predictor of a better outcome.

The potential role of molecular markers in tailoring surgical strategies is becoming of great interest (132). At present, there is some evidence that molecular characterization of the recurrent lesions should drive the surgeon in choosing between a curative-intent or a palliative-intent approach (133). Renaud et al. investigated differences in terms of outcomes after lung metastasectomy for colorectal cancers with different mutational profile (45).

The best outcome was observed in patients with tumors expressing protein K-rat sarcoma (KRAS) wild type, although long term survival was reported also when mutant KRAS was present. Conversely, patients presenting mutant B-RAS subfamily (BRAF) had an overall survival 3.5 times shorter than patients with mutant KRAS. Nonetheless, mutant BRAF was more often associated with presence of multiple metastatic lesions and higher nodal involvement, this may somehow explain the aforementioned results. In the studies included in our review, the molecular subtype did not appear to significantly impact the outcomes of repeat pulmonary resections.

Targeted therapy aims at inhibiting cell growth/spread by specifically targeting growth factors, signaling molecules, cell-cycle proteins, modulators of apoptosis and angiogenesis and other molecules involved in cancer pathogenesis. These treatments have improved the outcomes of several malignancies, such has breast and colorectal cancer (134). Metastases are known to have an increased genetic instability. This may lead to rapid growth of intralesional and interlesional heterogeneity, enabling more frequent occurrences of novel genetic variants. The new cells expressing a modified genotype can thus be resistant to therapy, and this escape mechanics leads to a selective advantage with reemergence of metastatic disease (135). Biological heterogeneity can therefore limit the results of targeted therapy. In several tumors, such as colorectal cancer, drug resistance to immunotherapy and partially to targeted therapy remains a major drawback (136). In a recent review, Cheung et al. depicts an ideal scenario where induction or definitive chemotherapy are supported by the surgical local control of drug-resistant metastatic foci (6).

Despite targeted and biological therapies may play a prominent role in the treatment of metastatic and systemic disease, the best outcomes are achieved with the association of surgery and chemotherapy. From our analysis, it appears evident that, at present, even the use advanced chemotherapeutic agents could not replace the role of redo metastasectomies or other strategies for local control, while a synergic approach remains the gold standard.

Immunotherapy was defined as “the breakthrough of the year” in 2013 (137). This therapy aims at enhancing the immunological response of the host against the cancer cells and its use in clinical practice achieved remarkable results in the treatment of several malignant disorders. It is commonly regarded as generally safe, with no important side-effects, albeit immune-related adverse events leading to endocrinological problems have recently been described (138).
The role of anti-tumor vaccines can be of great interest as the availability of good quality cancer specimens may aid the development of vaccines based on tumor cells (139). Only one study investigated the administration of an anti-tumor vaccine as an adjuvant therapy in pulmonary metastases from melanoma (140). Among the anti-tumor vaccines, Canvaxin failed to improve outcomes in a phase three study (141). Results of trials involving granulocyte-macrophage colony-stimulating factor are equivocal, albeit showing some promising features in the adjuvant treatment of melanoma (142).

Redo metastasectomy in frail patients

In the setting of repeat metastasectomies, patients’ frailty is often a concern that could potentially have an impact on surgical strategy. Nevertheless, in this review frailty did not appear to be factor affecting surgical or therapeutic management. Elderly patients are commonly thought to be more prone to surgical complications and pharmacological side effects. Moreover, frail patients with cancer more often experience chemotherapy toxicity, especially when combination therapies are administered (143). Kim et al. in 2015 (144) reported that elderly patients with locally advanced or metastatic colorectal cancer are more often under-staged and under-treated. To a certain extent, this is also caused by the lack of guidelines and clinical trials aiming at improving treatments’ effectiveness while reducing side effects. Certainly, a more specific and agreed definition of “frailty” would be helpful for a more accurate risk assessment and to improve therapeutic strategies. In 2013, an expert consensus defined frailty as: “a medical syndrome with multiple causes and contributors that is characterized by diminished strength, endurance, and reduced physiologic function that increases an individual’s vulnerability for developing increased dependency and/or death” (145).

The non-age adjusted version of the Charlson’s Comorbidity Index was used in several of the papers selected for this review, and in most of them we did notice a relevant correlation between its score and patients’ prognosis (146).

At Thoracic Surgery Unit of Tor Vergata University, a sizeable cohort of frail patients underwent redo pulmonary metastasectomy under non-intubated anesthesia with encouraging results (147). In this setting, non-intubated anesthesia proved effective in reducing systemic inflammatory stress without affecting immunological response (148), as in the non-intubated patients there was reduction of natural killer lymphocytes and less production of interleukin 6. These events could explain the lower incidence of postsurgical infections and the lower morbidity rate reported in the non-intubated group. However, there was not a positive effect on long-term survival, since both disease-free survival and overall survival after surgery were comparable to those of patients operated under general anesthesia (49). Nevertheless, the non-intubated patients experienced a longer—yet not statistically significant—disease-free survival. The small sample size makes this study of limited scientific value, still this non-significant trend shown could be explained by the occurrence of a more active cellular-mediate response, which has been previously demonstrated to be less reduced after non-intubated operations (149).

Analysis of survival

The analysis of survivals was available in all the examined

**Table 2** Calculated mean survivals from the first redo among the different records

<table>
<thead>
<tr>
<th>Study</th>
<th>Histology</th>
<th>Patients (n)</th>
<th>Mean OS (months)</th>
<th>5-year OS (%)</th>
<th>Mean pre DFI (months)</th>
<th>Mean post DFI (months)</th>
<th>5-year DFS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menna et al.</td>
<td>Colorectal</td>
<td>92</td>
<td>30</td>
<td>–</td>
<td>61</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Welter et al.</td>
<td>Colorectal</td>
<td>33</td>
<td>72.6</td>
<td>53.8</td>
<td>16.8</td>
<td>15.2</td>
<td>–</td>
</tr>
<tr>
<td>Rena et al.</td>
<td>Colorectal</td>
<td>7</td>
<td>42.5</td>
<td>50</td>
<td>20.3</td>
<td>–</td>
<td>55</td>
</tr>
<tr>
<td>Sakamoto et al.</td>
<td>Colorectal</td>
<td>5</td>
<td>22</td>
<td>–</td>
<td>15</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td>Mizuguchi et al.</td>
<td>Hepatocellular</td>
<td>5</td>
<td>65</td>
<td>67*</td>
<td>6.4</td>
<td>–</td>
<td>28</td>
</tr>
<tr>
<td>Han et al.</td>
<td>Urothelial</td>
<td>2</td>
<td>10</td>
<td>–</td>
<td>10</td>
<td>3.5</td>
<td>37.5</td>
</tr>
</tbody>
</table>

*at 3 years. OS, overall survival; DFI, disease free interval; DFS, disease free survival.
papers, although given the different starting points, in some cases this was incomplete or confounding. We therefore decided to present only those studies with clear and complete data of survivals and outcomes, which are summarized in Table 2. Predictably, more comprehensive data were found for overall survival, which we found ranging from 10 to 72 months with a 5-year survival rate of approximately 50%. This, which appears like a remarkably good result, must be carefully interpreted. Interestingly, the disease-free interval after redo metastasectomy was quite long in one of the largest series (26) providing, according to us, more evidence to support this procedure.

The most common site of recurrence after redo pulmonary metastasectomy remains the lung, and only three papers document non-pulmonary recurrence after the redo resections (11,26,41). This observation reinforces a common concept about the effectiveness of redo operations for a disease that tends to be confined in the lungs.

Our analysis showed that in general, disease-free interval before the redo metastasectomy, despite different temporal cut-offs used, was the most frequently reported factor affecting overall survival. For colorectal cancer, carcino-embryonic antigen (CEA) preoperative value, mediastinal lymph nodal status and number of metastases were the also frequent prognostic indicators (Figure 4), whereas many more other variables affected prognosis in metastases from sarcomas (Figure 5).

Selection effect

In 2015, the Tor Vergata Group observed that patients undergoing more than one pulmonary metastasectomy displayed a longer survival compared to those who underwent a single resection (11). This large retrospective study showed that 65% of patients undergoing repeated metastasectomies were alive after 5 years, compared to the 42% who underwent only one metastasectomy. This finding was confirmed by other authors who investigated patients with other types of tumors (10). Three or more redo pulmonary metastasectomies favored prolonged survival in patients with (150) and successful resection of recurrent metastatic lesions accomplished a favorable survival despite the number of operations (58,61).

This unexpected behavior seems to be an evident and unexplainable oncological paradox. How can a recurrent tumor entail longer survival? Could the chance of performing repeated resections create somehow more favorable conditions for survival in these patients? Two prominent and experienced investigators were invited to review and interpret these results. The analysis was published in the Journal of Thoracic and Cardiovascular Surgery with the title “Survival is higher after repeat lung metastasectomy than after a first metastasectomy: too good to be true?” (151).

In first instance, this comparison judged was inappropriate, because the two treatment strategies were not randomly assigned. These patients were not indeed allocated to 2 established subgroups of either single metastasectomy or repeated metastasectomies.

The selection of patients for any metastasectomy was based on clinical evaluation at the time of surgery, which still represents a valid influencing factor. The 2 cohort of patients presented rather different chances of long-term survival, as surgical candidates for redo metastasectomies had more likely a better fitness status and presented with slower-growing and more resectable disease. Conversely, patients that were considered inoperable for recurrent metastases, were surely more frail and/or presented a more aggressive cancer. Thus, the difference in survival may well be caused by the “a priori” different survival between groups, with metastasectomies only performed in patients destined to a longer survival.

The importance of the denominator must also be taken into account. The number of suitable candidates for a second, third and so on metastasectomy is significantly lower than the number of patients who can tolerate only one resection. This leads to inevitable bias in calculating all percentages, as well as in the use of the Kaplan-Meier method of analysis.

Nonetheless, lung metastases are rarely a cause of death. It is therefore rather unlikely that the initial flat portion of the survival curve after pulmonary metastasectomy is a direct result of the surgical procedure. More realistically, this results from the selection of patients with higher chances of postoperative survival (152).

Ultimately, this active selection of fit surgical candidates with slow growing disease for redo lung metastasectomy is enhanced by its own repetition (153), causing the differences in survival to become progressively more significant as the time goes by.

Conversely, after the first redo operations, both disease-free interval and overall survival decreases as the number of operations increases (11). This behavior appears more understandable, and could be caused by the denominator effect and also by the occurrence of more aggressive molecular subtypes of metastatic cells.
Survival effect

Does redo metastasectomy prolong survival? The benefit of an aggressive surgical treatment for patients with recurrent pulmonary metastases has not been unequivocally proven yet (5,6). Nevertheless, according to our review, neither targeted therapy, immunotherapy and even molecular subtype strategies have significantly modified the outcomes of repeat lung resections. In addition, none of these therapies have shown convincing results when used alone.

On the other hand, a large bulk of evidence supports the role of redo metastasectomy when performed according to the correct indications. The majority of the recurrent metastases considered to be surgically resectable are usually slow-growing malignancies (151), their response to cytotoxic therapies is therefore poor. It is our experience that the disease-free interval after the first redo lung metastasectomy is usually quite long (26). Furthermore, recurrences after repeat resection tend to remain confined in the lungs, as the chance of distant relapses is rather low. In this setting, local-control strategy like surgery seems to be justifiable.

Slow-growing single or few metastases represent the correct indication for repeat lung resections. Conversely, the presence of multiple and/or bilateral metastases contraindicates repeated procedures, especially if they have arisen after the first redo operations. This scenario is likely to derive from a more selective growth of a rather aggressive malignant cluster of cells. Nonetheless, in the rare instance of a life-threatening location of recurrent metastatic lesions, it is reasonable to accomplish resection (9).

Early diagnosis of recurrence is of paramount importance for long term prognosis. Detecting lung metastases is quite easy nowadays with the use of computed tomography, and other methods like positron emission tomography and radiomics techniques are excellent valid aids (154).

Operative mortality for redo operations is negligible and morbidity is generally quite low, also in frail patients. The following criteria remaining pivotal to accomplish an effecting redo lung metastasectomy: controlled or controllable extrathoracic disease; adequate cardiopulmonary reserve; technically feasibility to resect all detectable metastases, preferring parenchyma-sparing procedures.

A proficient thoracic surgeon should have sufficient experience with several different surgical approaches, both open and minimally-invasive, in order to tailor the operation for maximal effectiveness and minimal surgical trauma.

In 1999 our mentor Professor Mineo developed a new transxiphoid surgical technique, that combines the advantages of minimally-invasive access with the possibility of manually palpating both lungs to detect presence of nodules (155). The transxiphoid approach may be a good alternative to large thoracotomies, especially in the setting of multiple redo operations.

Finally, the evolution towards non-intubated surgical procedures in several, expanded the indications of surgery to the most frail patients with resectable pulmonary metastasis, avoiding the side-effects of general anesthesia.

Summary of evidence

Data retrieved from available literature provides interesting results for both current evidence and implications for future research.

First of all, the lack of guidelines for redo pulmonary metastasectomy has been underlined, caused by the absence of clear evidence on the effectiveness of lung metastasectomy.

Secondly, the review has demonstrated that redo metastasectomy does not carry a significant increment of perioperative mortality or morbidity.

Thirdly, patients undergoing redo metastasectomies have longer survival when compared to those undergoing only one pulmonary metastasectomy, but this may well be the result of an active selection of patients with higher chances of survival.

Fourth, whenever the lesion is resectable and the surgical risk is low, redo lung metastasectomy is worthwhile. At present, even the advanced antiblastic therapy and chemotherapeutic agents could not replace redo metastasectomies and local-control strategies, whereas a synergic strategy remains the gold standard. The outcome mainly depends on the biology of the tumor, hence the predictable importance of targeted therapy.

Last but not least, data retrievable from the literature are heterogeneous and sometimes confounding. Established guidelines deriving from multicenter prospective efforts are certainly desirable.

Conclusions

In conclusion, lung metastases can be resected with low risk and are a tempting target. While their removal may be a rewarding surgical strategy, actual proof of a true survival benefit is still lacking. The idea that longer survival is an
effect of repeated operations cannot be reliably stated based on observational data. Nevertheless, none of the alternative therapies have shown results comparable to surgery. At present, non-surgical therapies cannot replace redo metastasectomies and local-control strategies, while synergic therapies that include redo metastasectomy are considered the current gold standard.

We thank the editors for having entrusted us with such a challenging, yet fascinating topic.

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at: http://dx.doi.org/10.21037/jtd-19-4064). The series “Pulmonary Metastases” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: All authors are accountable for all aspects of this work in ensuring that questions related to the accuracy or integrity of any part of this work are appropriately investigated and resolved.

Provenance and Peer Review: This article was commissioned by the Guest Editor (Khosro Hekmat) for the series “Pulmonary Metastases” published in Journal of Thoracic Disease. The article was sent for external peer review organized by the Guest Editor and the editorial office.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


125. de Baère T, Aupérin A, Deschamps F, et al. Radiofrequency ablation is a valid treatment option for lung metastases:


141. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized double-blind, phase 3 study of the specific active immunotherapy agent, Onamelatucel-L (Canvaxin™), compared to placebo as a postsurgical adjuvant in AJCC stage IV melanoma. Presented at the Society of Surgical Oncology Annual Meeting; March 23-26, 2006; San Diego, CA. Abstract 12.


151. Treasure T, Mineo TC, Ambrogi V, et al. Survival is higher after repeat lung metastasectomy than after a first


Cite this article as: Ambrogi V, Tamburrini A, Tajé R. Results of redo pulmonary metastasectomy. J Thorac Dis 2020. doi: 10.21037/jtd-19-4064